1-10 of 10
Hui Huang, PhD, MBA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Hui Huang, PhD MBA
Journal: Blood
Blood (2016) 128 (22): 3081.
https://doi.org/10.1182/blood.V128.22.3081.3081
Published: 2016
Journal Articles

A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia

Elias J. Jabbour, MD, Maral DerSarkissian, PhD, Mei Sheng Duh, Nora McCormick, MSc, Wendy Y. Cheng, MPH, MPhil, Lisa J. McGarry, MPH, Ariadne Souroutzidis, BA, Hui Huang, PhD MBA, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 5189.
https://doi.org/10.1182/blood.V128.22.5189.5189
Published: 2016
Journal Articles

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Moshe Yair Levy, MD, Lisa J McGarry, MPH, Hui Huang, PhD MBA, Stephanie Lustgarten, PhD, Christopher Nieset, PharmD, Frank G Haluska
Journal: Blood
Blood (2014) 124 (21): 3154.
https://doi.org/10.1182/blood.V124.21.3154.3154
Published: 2014
Journal Articles

Comparative Efficacy Among 3 rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors

Jeffrey H. Lipton, MD PhD, Dhvani Shah, MS, Vanita Tongbram, MBBS, MPH, Manpreet K Sidhu, BA, PhD MBA, Hui Huang, PhD MBA, Lisa J McGarry, MPH, Stephanie Lustgarten, PhD, Neil Hawkins, PhD
Journal: Blood
Blood (2014) 124 (21): 4551.
https://doi.org/10.1182/blood.V124.21.4551.4551
Published: 2014
Journal Articles

Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).

Lisa J McGarry, MPH, Chakkarin Burudpakdee, PharmD, Smeet Gala, MS, Arpamas Seetasith, PhD, Merena Nanavaty, MS, Hui Huang, PhD MBA
Journal: Blood
Blood (2014) 124 (21): 5524.
https://doi.org/10.1182/blood.V124.21.5524.5524
Published: 2014
Journal Articles

Real-World Prescribing Patterns with Ponatinib Among New and Ongoing US Patients

Lisa J McGarry, MPH, Greg Wolfe, PharmD, Ann Steagall, BSN, RN, OCN, Hui Huang, PhD MBA
Journal: Blood
Blood (2014) 124 (21): 5521.
https://doi.org/10.1182/blood.V124.21.5521.5521
Published: 2014
Journal Articles

Comparative Efficacy Among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients After Failure Of 2 nd Generation Tyrosine Kinase Inhibitors (2G TKIs)

Jeff H. Lipton, PhD, MD, Peter Bryden, MSc, BSc, Manpreet K Sidhu, BA, PhD, MBA, Hui Huang, PhD, MBA, Lisa J McGarry, BA, MPH, ABD DSc, Stephanie Lustgarten, PhD, Beth Woods, MSc, BA, Neil Hawkins, PhD
Journal: Blood
Blood (2013) 122 (21): 4010.
https://doi.org/10.1182/blood.V122.21.4010.4010
Published: 2013
Journal Articles

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Hui Huang, PhD, MBA, Sanggyu Choi, PhD, Deyanira Corzo, MD
Journal: Blood
Blood (2011) 118 (21): 1864.
https://doi.org/10.1182/blood.V118.21.1864.1864
Published: 2011
Journal Articles

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Si-Tien Wang, MS, Hui Huang, PhD, MBA, Abbie Ba-Mancini, BS, MBA, Hongliang Shi, MS, Kristina Chen, MS, Caroline Korves, ScD, Ravinder Dhawan, PhD, Andrew Cakana, FRCPath, MD, Helgi van de Velde, Dixie-Lee W. Esseltine, MD, FRCPC, Mei S. Duh, ScD, MPH
Journal: Blood
Blood (2010) 116 (21): 2563.
https://doi.org/10.1182/blood.V116.21.2563.2563
Published: 2010
Journal Articles

An Economic Evaluation of Bortezomib-Based Induction Therapy in Double Transplant Protocols for Newly Diagnosed Multiple Myeloma Patients

Si-Tien Wang, BA, MS, Mei Sheng Duh, MPH, ScD, Hui Huang, PhD, MBA, Leigh Ann White, PhD, Eva Chang, MPH, Dixie-Lee Esseltine, MD, Jing L. Marantz, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2386.
https://doi.org/10.1182/blood.V112.11.2386.2386
Published: 2008